Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa
- 18 October 2019
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 236 (1) , 25-30
Abstract
Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients’ data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II–III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn’s disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.Keywords
This publication has 18 references indexed in Scilit:
- Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativaReviews in Endocrine and Metabolic Disorders, 2016
- Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source softwareJournal of the European Academy of Dermatology and Venereology, 2015
- HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab studyJournal of the European Academy of Dermatology and Venereology, 2015
- Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease EvaluationDermatology, 2015
- European S1 guideline for the treatment of hidradenitis suppurativa/acne inversaJournal of the European Academy of Dermatology and Venereology, 2015
- Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativaJournal of Dermatological Treatment, 2011
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1βBritish Journal of Dermatology, 2011
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic ReviewAmerican Journal of Gastroenterology, 2011
- Quality of life impairment in hidradenitis suppurativa: A study of 61 casesJournal of the American Academy of Dermatology, 2007
- Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean?Journal of Investigative Dermatology, 2005